bYoRNA

bYoRNA is a French early-stage (3M€ of pre-seed funding) startup focusing on the bioproduction of therapeutic mRNA in recombinant yeast cells for cancer immunotherapies, gene editing and infectious disease vaccines. This is a paradigm shift from the complex and expensive current IVT mRNA production. The technology is protected by a CNRS patent of which we have the exclusive license.

Advantages of in vivo production Vs IVT:

• more efficient (easier to produce long mRNA >5k nt) ;
• less immunogenic (no dsRNA) ;
• far cheaper.

We have secured partnerships with DYADIC , a Nasdaq company, , and TRON, the German mRNA research institute created by the founders of BIONTECH.

The company has been founded by Thierry ZIEGLER (CTO), a former bioproduction executive from MERCK, SANOFI and CELLECTIS, and Pascal VIGUIE (CEO), a high tech entrepreneur with a past 30M€ exit.

Members of our Scientific Committee include :

• Dr. Uwe Gottschalk (former CSO of Lonza) ;
• Dr. Chantal Pichon (patent inventor, INSERM France + Charity Berlin) ;
• Dr. Jeff Coller (mRNA professor at John Hopkins).

We have already produced a 2,000-nucleotide luciferase mRNA and an 8,000 von Willebrand Factor (vWF) mRNA as proof-of-concept and we plan to test our mRNA in two animal models by the end of the year. We are cca 3-year away from being GMP.